Comparison
The two clinic staples of GH optimization: one GHRH analog, one ghrelin-receptor secretagogue, and why they are so often stacked.
Sermorelin works the GHRH receptor side and ipamorelin the ghrelin-receptor side; clinics pair them because the two pathways amplify each other. Individually, both have thin adult outcome evidence.
GHRH analogs and ghrelin-receptor secretagogues act synergistically in endocrine studies: the combination produces larger GH pulses than either alone. The stack imitates studied physiology, though the combined product has never been outcome-tested.
Sermorelin has the longer history: an FDA-approved pediatric diagnostic in the 1990s, later discontinued for business reasons with FDA confirming it was not withdrawn for safety. Ipamorelin has cleaner comparative selectivity but failed its 2024 FDA compounding committee vote for 503A bulk use. Both are WADA-prohibited.
Sermorelin programs commonly describe 200 to 500 mcg before bed; ipamorelin 100 to 300 mcg one to three times daily or paired pre-bed. Both are daily subcutaneous injections in 8 to 12 week or ongoing programs.
| Dimension | Sermorelin | Ipamorelin |
|---|---|---|
| Overall evidence grade | B | D |
| Evidence label | Moderate human evidence | Limited human evidence |
| Regulatory status | Varies by product and jurisdiction | Investigational / not approved |
| Editorial confidence | Moderate confidence | Moderate confidence |
| Efficacy | 3/5 emerging | 1/5 limited |
| Safety | 2/5 limited | 1/5 limited |
| Regulatory risk | 3/5 moderate | 5/5 very high |
| Product quality risk | 4/5 high | 4/5 high |
| Primary claim categories | Historical Geref product context, Pediatric growth hormone deficiency, Pituitary growth hormone reserve evaluation, GHRH pathway claims, Product-quality and eligibility risks | Investigational GH secretagogue context, Healthy-volunteer PK/PD, Postoperative-ileus registry context, FDA compounding-policy review, Product-quality and regulatory risks |
Sermorelin is a historical GHRH reference with narrow pediatric GHD and diagnostic evidence, not a basis for adult anti-aging, body-composition, performance, or wellness claims.
Ipamorelin is an investigational GH secretagogue with compounding-policy concerns. The current evidence is limited to healthy-volunteer PK/PD, postoperative-ileus registry context, and FDA 503A review rather than approved GHD, anti-aging, body-composition, recovery, or stack claims.
Accessed 2026-06-09.
Federal Register notice identifying historical Geref treatment and diagnostic uses, discontinued marketing status, and FDA's not-withdrawn-for-safety-or-effectiveness determination.
WADA. The 2026 Prohibited List: growth hormone-releasing factors 2026.
Accessed 2026-06-09.
WADA lists growth hormone-releasing hormone analogues, including sermorelin, under prohibited peptide hormones, growth factors, related substances, and mimetics.
FDA. October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting 2024.
Accessed 2026-06-09.
FDA meeting summary reporting PCAC votes against placing ipamorelin free base or ipamorelin acetate on the 503A Bulks List because the available information did not support safety and efficacy in the reviewed contexts.
USADA. David Branch Receives Sanction for Violation of UFC Anti-Doping Policy 2019.
Accessed 2026-06-09.
Official USADA source stating that ipamorelin is a prohibited peptide-hormone / growth-factor substance under anti-doping rules that adopt the WADA Prohibited List.